Creso and CanniMed Canada negotiate groundbreaking deal
In terms of the agreement CPH has been appointed preferred distributor for CanniMed Canada in the European Union for the purpose of marketing all of the group’s medical cannabis brands to governments, authorised importers and distributors, institutions, pharmacies and individuals.
It is important to note that within the European market several countries including Germany and Denmark have already moved towards the legalisation of medical cannabis when recommended by a physician. Furthermore, countries such as Belgium and Austria have legislation in place to conduct clinical research.
CPH’s scalable revenue model sets it aside from many peers
Consequently, the potential to generate income from Prairie Plant Systems PPS products sold in the EU represents another revenue accretive development for CPH following the negotiation of several agreements in recent weeks. Importantly, this comes at a stage when many new industry entrants have long-range revenue visibility at best.
Given CanniMed’s high profile and 15 year growing history, this is a particularly important arrangement, and comes on the back of three other commercial agreements struck in the last three weeks which have resulted in CPH’s shares surging circa 35%.
It should be noted that this is an early stage company and it is impossible to predict share price responses, investors should seek independent financial advice if considering this company for their portfolio.
CanniMed sole GMP supplier for Health Canada’s initial medical marijuana program
CanniMed is licensed under the Access to Cannabis for Medical Purposes (ACMPR) and has the longest growing history as a result of the parent company, Prairie Plant Systems Inc, being the sole GMP supplier for the entirety of Health Canada’s initial medical marijuana program.
Consequently, the scale of distribution, supply chain optimisation and access to new markets facilitated by this agreement provide CPH with a significant boost in addition to bringing its range of human and animal cannabis derived products to market.
The two companies are an ideal fit, with CanniMed’s Chief Executive, Brent Zettl commenting, “Creso Pharma is the ideal partner to support our expansion into the European market as a result of their industry expertise in drug development, clinical research and contacts with influential medical centres interested in the implementation of clinical trials with medical cannabis”.
This was endorsed by CPH chairman, Boaz Wachtel who said, “Together we see tremendous opportunities to provide governments, medical cannabis patients and leading research institutions with standardised medicines that meet strict manufacturing guidelines, effectively supporting CPH’s near-term revenue generation”.
CPH continues to underpromise and outperform, providing share price momentum
Most recently CPH negotiated a binding letter of intent with a Swiss animal health company and Dutch veterinary product manufacturer and wholesaler. This followed the signing of its first distribution agreement in Central Europe, a development which will bring immediate revenue and cash flow.
A little over a week ago (Creso positioned to penetrate US$40 billion veterinary health market) FinFeed said, “It is only relatively early in the fourth quarter and CPH has achieved two of its goals and with significant events potentially occurring over the next six months, including the anticipated first quarter 2017 negotiation of development and commercialisation agreements in the important North American biopharmaceutical market, there is scope for CPH’s share price to rerate strongly”.
Investors like companies that hit milestones either on or ahead of time and CPH is quickly establishing a reputation for doing just that.
As can be seen below, management is ahead of schedule, having flagged the identification of distribution partners to increase Hemp Industries sales in new jurisdictions, as well as the signing of a development and commercialisation agreement with a leading North American biopharmaceutical company, with both of these goals mapped out for the first quarter of calendar year 2017.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of Maven Capital Pty Ltd (AFSL No. 418504). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.